Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

DWTX

+ Watchlist+ Portfolio

Dogwood Therapeutics, Inc.

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.08
52-Week Range
$0.90 – $7.04
Market Cap
$41.29M
P/E (TTM)
0.11
EPS (TTM)
10.26
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.57
PEG Ratio
—
Return on Equity
-35.58%
Return on Assets
-13.88%
Gross Margin
11.90%
Operating Margin
-18608.44%
Profit Margin
0.00%
Current Ratio
2.78
Debt/Equity
0.00
Total Debt
$117.95K
Free Cash Flow
$-9.85M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$36.46M

Market Snapshot

About

Dogwood Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases with significant unmet medical needs. The company's pipeline includes novel therapeutic candidates targeting various conditions, with a focus on precision medicine approaches. As a development-stage company, Dogwood is advancing its drug candidates through clinical trials and regulatory processes. The company does not yet have any commercialized products and generates no product revenue.